Abstract
3505 Background: KRAS and BRAF activating mutations (mut) are frequent in colorectal cancer (CRC). Both genes act in the ERK pathway, but they occur in different CRC subtypes and have different prognostic implications, suggesting they might entail disruptions in different signaling pathways. Methods: RNA extracted from 1378 formalin-fixed tissues was used for expression profiling on the Affymetrix-based ALMAC platform Colorectal Cancer DSA. KRAS G12S, G13V, G13C, G13D, G12R, G13A, G12V, G12D, G12G, G12C, G12A, G12G mut and BRAF V600 were assessed. BRAF mut vs KRAS mut and BRAF or KRAS mut versus double wildtype (wt) were compared. Statistical analysis of differential expression was performed with standard methods in R. Classifiers were constructed using AdaBoost and DLDA algorithms and performance estimated by cross-validation. Results: KRAS mut were found in 37%, BRAF mut in 8%. Outcome correlations were reported (Roth A,JCO 2010). To date, 244 hybridized samples were analyzed (25 BRAF mut, 91 KRAS mut),...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
